Hemostemix Announces the Appointment of Dr. Nadia Giannetti, MD, to its Scientific Advisory Board
Calgary, Alberta–(Newsfile Corp. – September 16, 2022) – Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) (« Hemostemix » or the « Company ») is pleased to announce the appointment of Dr. Nadia Giannetti, MD, to its Scientific Advisory Board.
Dr. Giannetti received her Medical Degree from McGill University. After training in cardiology at McGill, she went on to pursue a Fellowship in Heart Failure and Cardiac Transplantation at Stanford University in California. She returned to McGill to become an Attending Cardiologist and an Associate Professor in the Department of Medicine. Dr. Giannetti, along with her team participates in the care of over 1000 patients with heart failure. She is the former Chief of Cardiology at the McGill University Health Centre (2010-2021). Since 2021, she has been the Associate Physician-in-Chief for the Department of Medicine, McGill University Health Centre, and is the Medical Director of the Heart Failure and Heart Transplant program.
Dr Giannetti is a Clinical Researcher with an interest in personalized therapy for patients with dilated cardiomyopathy and optimizing clinical outcomes in patients living with heart failure. She is the co-Principal Investigator of a large initiative looking at the role of stem cells in personalized therapy for cardiomyopathy.
For the past 10 years, Dr. Giannetti has been an active member of the Canadian Heart Failure and Heart Transplant Guidelines. She has led multiple multi-center clinical trials as a local and national principal investigator. She is the Program lead for a large research initiative entitled the Courtois Cardiovascular Signature Program (cvsignature.ca) and the Director of the Courtois Cardiovascular Biorepository.
Dr. Giannetti is very active in the Canadian Heart Failure and Transplant landscape. She is past president of the Canadian Cardiac Transplant Group, has been on the Board of Directors of the Canadian Heart Failure Society and Governance Committee of the Canadian Cardiovascular Society. For the past 10 years, she has been an active member of the Canadian Heart Failure and Heart Transplant Committees and has been a co-author on multiple published Canadian Heart Failure and Heart Transplant Guidelines.
« Hemostemix is delighted to welcome Dr. Giannetti to the Scientific Advisory Board, as her stem cell cardiomyopathy clinical research, cardiology practice, and interest in personalized therapy for patients who have dilated cardiomyopathy aligns exactly with ACP-01’s therapeutic benefits » stated Thomas Smeenk, CEO. « I look forward to her counsel as we move forward to follow-up the results of three previous heart studies that demonstrate ACP-01 is safe and efficacious as a treatment dilated and ischemic cardiomyopathy, » Smeenk said.
ABOUT HEMOSTEMIX
Hemostemix is an autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, and is scaling a patient’s blood-based stem cell therapeutics platform that includes angiogenic cell precursors, neuronal cell precursor and cardiomyocyte cell precursors. Seven studies including 260 ACP-01 recipients define its safety and efficacy profile as a treatment for heart diseases such as Dilated and Ischemic Cardiomyopathy, Angina, and diseases of Ischemia such as Critical Limb Ischemia. The Company owns 91 patents across five patent families. For more information, please visit www.hemostemix.com.
For further information, please contact: Thomas Smeenk, President, CEO & Co-Founder
EM: tsmeenk@hemostemix.com PH: 905-580-4170
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Information: This news release contains « forward-looking information » within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to: an appointment to the Scientific Advisory Board in relation to the lead product ACP-01, and the retrospective study of ischemic and dilated cardiomyopathy, and the commercialization of ACP-01. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix’s current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of the litigation that Hemostemix is pursuing or defending (the « Litigation« ); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix’s services and products; competition and Hemostemix’s competitive advantages; and Hemostemix obtaining satisfactory financing to fund Hemostemix’s operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemis mayface; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix’s markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression;the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix’s ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix’s disclosure documents on the SEDAR website at www.sedar.com. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.